Nuvation Bio INC

Nuvation Bio Inc. announced the full exercise of the over-allotment option for its 0.75% Convertible Senior Notes due 2032, raising a total of $287.5 million.

Nuvation Bio Inc. has priced an offering of $250.0 million in aggregate principal amount of 0.75% Convertible Senior Notes due 2032, with an option for underwriters to purchase an additional $37.5 million.

Nuvation Bio Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of directors and ratification of its independent auditor.

Nuvation Bio announced first quarter 2026 financial results, with IBTROZI net product revenues of $18.5 million and a significant increase in collaboration and license revenue to $64.7 million, alongside strategic updates including the acquisition of Japan rights for safusidenib.

Nuvation Bio announced robust fourth-quarter and full-year 2025 financial results, highlighting strong IBTROZI adoption and pipeline advancements.

Nuvation Bio announces a significant licensing deal with Eisai for its cancer drug IBTROZI, alongside strong preliminary Q4 and full-year 2025 sales results and a robust cash position.

Nuvation Bio Inc. reported increased revenues and a strengthened cash position for Q3 2025, driven by the commercial launch of IBTROZI in the U.S. and regulatory approvals in Japan and China.

Nuvation Bio reports significant revenue growth driven by the U.S. launch of IBTROZI and a strengthened financial position following a $200 million non-dilutive financing.

Nuvation Bio reports Q1 2025 financial results, highlighting revenue growth from collaborative agreements and progress in clinical development programs.

Nuvation Bio's Q3 2024 report details a significant net loss driven by acquired R&D, alongside progress in clinical trials and a key NDA submission.

Nuvation Bio's second quarter results for 2024 reflect the impact of the AnHeart Therapeutics acquisition, including a significant charge for acquired in-process research and development.

Nuvation Bio reports a net loss of $14.8 million for the first quarter of 2024, with a focus on advancing its oncology pipeline and integrating the recent acquisition of AnHeart Therapeutics.

Nuvation Bio reports its first product revenue from IBTROZI's U.S. launch, but faces increased operating losses and substantial funding needs for its pipeline development.

Nuvation Bio Inc. reports its 2024 financial results, highlighting progress in its oncology pipeline, including the FDA's acceptance of the NDA for taletrectinib.

Nuvation Bio Inc. files an amendment to its annual report on Form 10-K to include previously omitted information regarding directors, executive compensation, and corporate governance.

Nuvation Bio Inc. released its 10-K filing, detailing its clinical-stage oncology pipeline, financial status, and strategic direction for 2023.

Philippe Sauvage, Chief Financial Officer of Nuvation Bio Inc., reported multiple transactions in common stock on July 15, 2026.

Nuvation Bio Inc. reports that Chief People Officer Stacy Markel sold a significant number of Class A common stock shares through a pre-arranged 10b5-1 trading plan.

Kerry Wentworth, Chief Regulatory Officer of Nuvation Bio Inc., sold 63,000 shares of Class A Common Stock for $2.93 per share under a pre-arranged 10b5-1 plan.

Nuvation Bio Inc. CFO Philippe Sauvage sold 47,668 shares of Class A Common Stock for an average price of $6.00, as part of a pre-arranged 10b5-1 trading plan.

Director Robert Mashal acquired 25,000 shares of Nuvation Bio Inc. (NUVB) at a price of $4.73 per share.

Nuvation Bio Inc. reports that Director Vernon W. Anthony acquired stock options for 123,397 shares of Class A Common Stock.

Nuvation Bio Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for May 21, 2026, to elect directors, ratify auditors, and vote on executive compensation.

Nuvation Bio is holding its annual meeting of stockholders on May 21, 2025, to vote on director elections, auditor ratification, and executive compensation.

Nuvation Bio issues a supplement to its proxy statement to clarify voting approval standards for the proposals at the Annual Meeting of Stockholders on September 3, 2024.

Nuvation Bio is holding its annual meeting on September 3, 2024, to vote on director elections, auditor ratification, executive compensation, preferred stock conversion, and a potential meeting adjournment.

BlackRock, Inc. has filed a Schedule 13G, reporting a beneficial ownership of 6.4% in Nuvation Bio Inc.'s common stock as of June 30, 2025.

FMR LLC and its affiliates, along with Abigail P. Johnson, have reported a combined beneficial ownership of 15.0% of Nuvation Bio Inc.'s Class A Common Stock as of March 31, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 4.9% beneficial ownership stake in Nuvation Bio Inc.'s Class A Stock as of March 31, 2025.

FMR LLC and its affiliates, along with Abigail P. Johnson, reported a continued beneficial ownership of 13.5% of Nuvation Bio Inc.'s Class A Common Stock as of December 31, 2024.